ambossIconambossIcon

Glaucoma

Last updated: December 18, 2024

Summarytoggle arrow icon

Glaucoma is a group of eye diseases associated with acute or chronic destruction of the optic nerve with or without concomitant increased intraocular pressure (IOP). In the US, glaucoma is the second leading cause of blindness in adults following age-related macular degeneration (AMD). The two main types are open-angle glaucoma and angle-closure glaucoma. Open-angle glaucoma accounts for 90% of all cases of glaucoma, is slowly progressive, and is initially often asymptomatic, but leads to bilateral peripheral vision loss over time. With appropriate treatment that lowers IOP (e.g., topical prostaglandins), progression can be stopped before severe damage occurs. Acute angle-closure glaucoma, on the other hand, is characterized by the sudden onset of a painful, red, and hard eye in combination with frontal headache, blurry vision, and halos appearing around lights. Immediate initiation of medical therapy (e.g., timolol eye drops and IV acetazolamide) is crucial to rapidly decrease IOP and prevent vision loss. Chronic angle-closure glaucoma manifests and is managed similarly to open-angle glaucoma.

Icon of a lock

Register or log in , in order to read the full article.

Epidemiologytoggle arrow icon

References:[1][2]

Epidemiological data refers to the US, unless otherwise specified.

Icon of a lock

Register or log in , in order to read the full article.

Overviewtoggle arrow icon

Important types of glaucoma
Open-angle glaucoma Angle-closure glaucoma
Risk factors
Clinical features
  • Initially often asymptomatic
  • Bilateral, progressive visual field loss (from peripheral to central)
Treatment
Overview of drugs used to treat glaucoma
Mechanism of IOP decrease Drugs Mechanism of action Adverse effects

↓ Synthesis of aqueous humor

  • Via decrease in cAMP
Aqueous humor outflow
  • Decreases resistance through uveoscleral flow

DIrty PARASites PROSper on ALPine BETonies: DIuretics, PARASympathomimetics, PROStaglandins, ALPha agonists, and BETa blockers are drugs for the treatment of glaucoma.

References:[2]

Icon of a lock

Register or log in , in order to read the full article.

Pathophysiologytoggle arrow icon

References:[3][4]

Icon of a lock

Register or log in , in order to read the full article.

Open-angle glaucomatoggle arrow icon

Definition

  • Open-angle glaucoma (also chronic glaucoma): generally bilateral, progressive loss of optic nerve fibers with open chamber angles (often with increased IOP), not caused by another systemic or local condition

Etiology [5]

Pathophysiology

Clinical features [5]

  • Initially often asymptomatic
  • Over time, nonspecific symptoms such as mild headaches, impaired adaptation to darkness
  • Generally bilateral, progressive visual field loss (from peripheral to central)
  • Arcuate scotoma: arch-shaped scotoma that starts from the blind spot

Diagnostics [5]

Treatment of open-angle glaucoma [5]

  • Indicated in all patients diagnosed with open-angle glaucoma (even if asymptomatic)
  • Options include medical therapy, laser surgery, and open surgery
  • Topical prostaglandins are most effective and usually used initially; other drugs (with a different mechanism) may be added if topical prostaglandins are unsuccessful.
    • No decrease in IOP with one drug: Discontinue and replace with another drug or treatment option.
    • Partial response to one drug: Consider combination therapy with other glaucoma medications or switch to an alternative single-agent therapy.
  • Goal of therapy (target IOP): ≥ 25% decrease in pretreatment IOP

Pharmacotherapy [5][6]

The following regimen is the most commonly followed and is also effective in patients with chronic angle-closure glaucoma refractory to laser peripheral iridotomy (see ''Treatment'' in angle-closure glaucoma for further details).

Interventional therapy [5]

Procedures that lower IOP by facilitating drainage of aqueous humor

Procedures that lower IOP by decreasing aqueous humor production

  • Cyclodestructive surgery
    • Indication: glaucoma refractory to other treatment options
    • Procedure: laser or cryosurgical destruction of the ciliary body

Prevention [5]

  • General screening for glaucoma is not considered cost-effective but is currently recommended in the following patient groups:
Icon of a lock

Register or log in , in order to read the full article.

Angle-closure glaucomatoggle arrow icon

Definition [6][11][12][13]

Etiology/risk factors

Pathophysiology [11][12][13][17][18]

Clinical features

Acute angle-closure glaucoma is a medical emergency, as it can cause permanent vision loss if left untreated!

Diagnostics

Approach [6][11][12][13]

Acute angle-closure glaucoma is vision-threatening and requires emergency ophthalmology evaluation as soon as the clinical diagnosis is suspected.

Do not use mydriatic drugs (e.g., atropine and epinephrine) during ophthalmologic examination in patients with acute angle-closure glaucoma! Moreover, do not cover the eye, since darkness induces mydriasis and worsens the condition! [11]

Tonometry [20][21]

Gonioscopy [12]

Slit-lamp examination [6][11][18]

Direct fundoscopy (with undilated pupils) [6][11][18]

Do not dilate the pupils to evaluate the fundus in suspected glaucoma!

Visual acuity [11][23]

Visual field testing [6][13][24]

  • Indication: all patients with glaucoma
  • Techniques
  • Characteristic findings
    • Glaucomatous visual field defects: a characteristic pattern of visual field defects as a result of glaucomatous optic neuropathy [18][24]
      • Early-stage: arcuate or double arcuate (ring) scotoma
        • Loss of peripheral vision especially of the superior and/or inferior hemifields
        • Sparing of central vision
      • Advanced stage
        • Tunnel vision: further constriction of peripheral vision
        • Total or near-total blindness: loss of peripheral and central vision with or without sparing of the temporal field

Treatment of acute angle-closure glaucoma [6][11][13][15][25]

Acute angle-closure glaucoma is an emergency and should be initially managed with IOP-decreasing medications that have a rapid onset of action. Once IOP has decreased, patients should undergo a definitive procedure as soon as possible to prevent recurrence.

General considerations

Initial pharmacotherapy

  • Indication: initiate in all patients as soon as a diagnosis of acute angle-closure glaucoma is made. [6][11][13][15]
  • Initial pharmacological regimen: There is currently no standardized recommendation for empiric management of acute angle-closure glaucoma. The following regimen may be followed with due consideration of any comorbidities. [6][11][13][15]
  • If IOP is still elevated after 30–60 minutes: The following should be given only under the guidance of an ophthalmologist. [15][25]
    • Repeat eye drops from above up to three times. [15]
    • Consider a systemic hyperosmotic agent if IOP remains high after 60 minutes of initiating therapy. [13][25]
      • In patients with nausea: IV mannitol
      • In patients without significant nausea [25]
        • Nondiabetic patients: oral glycerine [25]
        • Diabetic patients: oral isosorbide [11]
  • If IOP is decreasing: Examine for other signs of resolution of the acute attack. [6][13]

Urgent interventional therapy

  • Anterior chamber paracentesis
  • Urgent laser peripheral iridotomy (see ''Interventional therapy'' for details)
    • Indication: all patients within 24–48 hours of resolution of the acute attack [6]

Topical pilocarpine becomes effective only once IOP decreases to < 40 mm Hg.

Acute management checklist for acute angle-closure glaucoma [6][11][30]

  • Emergency ophthalmology consult
  • Place patient in a supine position.
  • Initiate pharmacotherapy as soon as the diagnosis is made.
  • Consider hyperosmotic pharmacotherapy if initial treatment is unsuccessful.
  • Supportive care, as needed
  • Admit patient or transfer to a hospital with ophthalmology department capable of performing LPI.

Treatment of chronic primary angle-closure glaucoma [6][11][12]

Chronic angle-closure glaucoma with pupillary block should be initially managed with laser surgery (e.g., peripheral iridotomy) or open surgery (iridectomy) to prevent the progression of glaucomatous optic neuropathy and consequent visual field loss. Long-term pharmacotherapy is required if IOP elevation is refractory to the intervention or in patients without pupillary block.

Interventional therapy [6][11][12][13]

Acute angle-closure glaucoma and chronic primary angle-closure with pupillary block

Chronic primary angle-closure glaucoma without pupillary block [6]

Secondary angle-closure glaucoma [6][31]

Icon of a lock

Register or log in , in order to read the full article.

Congenital glaucomatoggle arrow icon

Epidemiology

  • < 1% of children are born with the condition in the US.
  • Bilateral in ∼ 75% of cases
  • Most cases are diagnosed within the first year of life.

Etiology

Pathophysiology

Clinical features

Diagnostics

Therapy

Icon of a lock

Register or log in , in order to read the full article.

Start your trial, and get 5 days of unlimited access to over 1,100 medical articles and 5,000 USMLE and NBME exam-style questions.
disclaimer Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer